InnoStar

nonclinical Safety Evaluation Platform

Focus on R&D services
Empowering the healthcare industry

Shanghai InnoStar Bio-tech Co., Ltd. (InnoStar) was established in 2010. As a leading contract research organization, we strive for excellence through our services with high quality, win customers by recognized reputation, add values by technical innovation, and maintain efficiency by streamlined management. Our business scope covers screening and discovery services, nonclinical pharmacodynamics, nonclinical pharmacokinetics, nonclinical safety evaluation, clinical sample bioanalysis, biomarkers and translational research. InnoStar was listed on the STAR Market of Shanghai Stock Exchange on September 3, 2024 (Stock code: 688710).



NMPA GLP AUT | U.S.FDA GLP INSP | OECD GLP AUT | AAALAC AUT | 美国CAP AUT

SCOPE OF BUSINESS

InnoStar Provides One-stop Service From Nonclinical to Clinical Translation

PCC
- Screening and Discovery Services

IND
- Nonclinical Pharmacodynamics
- Nonclinical Pharmacokinetics
- Nonclinical Safety Evaluation

NDA
- Clinical Biological Sample Testing
- Biomarkers and Translational Research

Services of differentiated solutions designed by experts covering the life cycle of drug development

PROJECT EXPERIENCE

920+
Already served
New drug development clients

100+
Annual average IND package completed amount

30+
Annual NDA/BLA package completed amount

200+
We have served on both international and domestic "first-of-its-kind" innovative drug research and development projects.

140
Overseas IND Application Successful

3
FDA NDA/BLAs

注: 数据统计区间:2015-2024.12.31

Scan the QR code for more business inquiries

TOC

www.innostar.cn

One-stop Service from Nonclinical to Clinical Translation

InnoStar (HQ)

190,000+ Sqft 570+Staff)

NMPA GLP
2010/2015/2019/2022/2025

U.S. FDA GLP
2014/2018

OECD GLP
2012/2015/2017/2019/2024

AAALAC
2011/2014/2017/2020/2023

CAP
2015/2017/2019/2022

Nantong InnoStar

320,000+ Sqft 500+Staff

NMPA GLP
2019/2020/2021/2023

AAALAC
2019/2023

Shenzhen InnoStar

717,600+ Sqft

NMPA GLP
2023

AAALAC
2023

Platform Introduction

Introduction to the Platform

The non-clinical safety evaluation platform offers internationally recognized safety solutions to support drug development with advanced experimental animal technologies, diverse species resources, and regulatory expertise. It specializes in evaluating toxicity biomarkers, genotoxicity, addiction potential, ophthalmic safety, and cardiotoxicity, playing a crucial role in assessing the safety of cutting-edge drugs, including novel small molecules, biologics, bispecific/multispecific antibodies, ADCs, nanobodies, peptides, nucleic acid therapies, and cell/gene therapies (immune/stem cells, oncolytic viruses, AAV vectors).
InnoStar' s platform provides precision and compliance in safety assessments, accelerating the development of complex therapeutics through integrated in vitro/in vivo models and tailored safety strategies. The focus is on aligning technical excellence with global regulatory standards, ensuring rapid and safe translation from preclinical studies to clinical trials, and establishing trust among biopharma innovators worldwide.

Service content

- safety pharmacology
- general toxicology
- genetic toxicology
- Developmental and Reproductive Toxicology
- Immunotoxicity and immunogenicity
- carcinogenicity test
- Preparation safety and phototoxicity test
- Safety evaluation of inhaled formulations
- Dependency experiment
- Pathology
- clinical pathology
- Cross organizational TCR

Nonclinical Safety Evaluation Platform

FDA NMPA OECD
ICH harmonisation for better health
Pmda
Ministry of Food and Drug Safety



Safety pharmacology studies

Core portfolio

- **cardiovascular system**
  - -Calm dogs/pigs/monkeys: DSI and EMEA implantable/EMKA vest
  - -In vitro electrophysiology: potassium channels (hERG), sodium and calcium channels
- **respiratory system**
  - -Rats/mice: EMKA whole body volume mapping system
  - -Respiratory rate/tidal volume/minute ventilation
- **C. N. S**
  - -Rats/mice/sprague-dawes rats/monkeys:
  - -Functional observation combination experiment (FOB)
  - -Improved Irwin method
  - -Behavior, learning and memory, etc

complementary testing

- **Gastrointestinal system**
- **Urinary / renal system**



Species of animal

- Rats/mice
- squirrels
- dogs
- pigs
- monkeys

route of medication

- Oral (gavage, capsule, tablet) and nasogastric administration
- Intravenous (injection/drip), subcutaneous, intradermal, intra-abdominal, intramuscular injection
- Transdermal application, transmucosal (oral) administration, eye drops, nasal drops, and infiltration administration
- Subretinal injection / vitreous injection
- Inhalation administration/intratracheal administration
- Intratumoral injection
- Administration by vaginal/rectal/bladder instillation
- Intracerebral/intraventricular/subarachnoid injection/ intracranial implantation pump injection
- Intra-articular injection (knee/hip)
- Intramyocardial injection
- Administration was via the spleen

General toxicology tests

Type of test

- MTD, dose range determination test
- Single-dose toxicity test
- Repetitive dosing toxicity tests
- sensitivity test
- Hemolytic test
- Local irritation test
- In vivo photo toxicity test
- T cell-dependent antibody response test
- In vivo and in vitro tumor formation tests
- Tumor in the body

route of medication

- Oral (gavage, capsule, tablet) and nasogastric administration
- Intravenous (injection/drip), subcutaneous, intradermal, intra-abdominal and intramuscular
- Transdermal application, transmucosal (oral) administration, eye drops, nasal drops, and infiltration
- Subretinal injection/gas injection
- Inhalation administration/gastric administration
- Intratumoral injection
- Administration by vaginal/rectal/bladder instillation
- Intracranial injection/intraventricular injection/subarachnoid injection/intracranial implantation pump
- intraarticular injection
- Intramyocardial injection
- Administration was via the spleen

Species of animal

- Mice, rats, guinea pigs
- Rabbit, dog
- Non-human primates (including marmosets)
- miniature pig
- Golden hamster
- Immunodeficient mice
- Humanized animal model

Specimen collection

- blood
- urine
- semen
- milk
- cerebrospinal fluid
- aqueous humor
- Liver (biopsy)

Genetic toxicology tests

Core combination test

- Bacteria(Ames)
- In vitro and in vivo chromosomal aberration tests
- Genetic mutation tests (MLA, HPRT or XPRT)
- In vitro and in vivo micronucleus tests
- Comet test of multiple organs in vivo

clone

- Chinese hamster fibroblasts (CHL cells)
- Chinese hamster ovary cells (CHO cells)
- Mice lymphoma cells (L5178Y cells)
- Human lymphoblast (TK6 cells)

route of medication

- Oral gavage, intravenous (injection/drip), subcutaneous, intraperitoneal and intramuscular administration

Additional tests/ mechanism studies

- In vitro and in vivo Pig-a gene mutation tests
- In vitro genetic toxicity test of multiple biomarkers
- In vivo liver micronucleus test

Extracellular metabolic activation system:

- Rat S9 and human S9



Teratology and reproductive toxicity

Core projects

- Fertility and early embryonic toxicity tests (Seg I)
- Embryo-fetal developmental toxicity test (Seg II)
- Perinatal developmental toxicity test (Seg III)
- Combined test of reproductive toxicity I/II/III
- Perinatal developmental toxicity test enhanced by crab monkeys (ePPND)
- Non-human primate embryo-fetal development toxicity test (NHP, EFD)
- Multi-generational breeding trials

Professional evaluation projects

- Evaluation of blood-hemolysis barrier and placental transport
- Evaluation of rodent behavior
- Evaluation of growth and development and reflex function
- Bone development evaluation
- Non-human primate neurosis is a combination of academic assessment
- Human-like primate grip strength and mother-child interaction

Species of animal

- Mice, rats
- hare
- Non-human primates
- Humanized animal model

route of medication

- Oral (gavage, capsule, tablet) and nasogastric administration
- Intravenous (injection/drip), subcutaneous, intradermal, intramuscular
- Transdermal application and nasal administration
- Given via the vagina

Specimen collection

- Blood (mother, fetus)
- embryonic tissue
- maza
- semen
- milk
- skeleton



Immuno-toxicity and immunogenicity tests

Service content

- Immunotoxicity is routinely accompanied by general toxicology.
- immunogenicity

route of medication

- Intravenous (push/drip), subcutaneous, intradermal, intramuscular injection
- Inhalation/intratracheal administration

Animal species and genera

- Mice, rats
- Non-human primates (including marmosets)
- Rabbit
- Humanized animal model

Specimen selection

- Blood (PBMC)
- spleen



Service Advantages

Our institution has established detection platforms for humoral immunity (antibody titer detection) and cellular immunity (ELISPORT, ICS).
We have completed the immunogenicity screening of multiple projects, including traditional and novel preventive vaccines as well as therapeutic vaccines.

Carcinogenic test

carcinogenic test

- Carcinogenicity test in rats for 2 years
- Carcinogenicity test in 18-24 month old mice
- Carcinogenicity test in rasH2 transgenic mice for 6 months
- Carcinogenesis test in 6-month-old P53 gene knockout mice
- Tumor/carcinogenesis test in immunodeficient mice (cell therapy products)
- In vivo tumorigenicity test/in vivo tumorigenicity test (cellular therapy products)

Types of tumor marker auxiliary diagnosis





- Cytokeratin
- S-100、GFAP、Nurofilament
- Actin smooth muscle
- Chromogranin A
- Vimentin

Safety evaluation of inhalation preparations

service content

- Acute toxicity evaluation
- Repeated drug toxicity evaluation
- Stimulating research
- Allergic studies
- Pulmonary function evaluation (such as ventilation function evaluation, gas exchange function evaluation, etc.)
- Aerodynamic particle size distribution (ASAP) -Cascade impactor method (CI)
- Aerosol concentration analysis
- Bronchoalveolar lavage fluid (BALF) analysis and detection techniques

Animals can be evaluated

- rat/mouse
- cavy
- dog
- monkey

Formulations can be evaluated

- Aerosols (MDIs)
- Spray (Nebulizer)
- Powder aerosols (DPIs)
- liquid preparation

Method of administration

- Nebulization through the trachea
- Oral and nasal exposure
- Nasal administration
- Nasal drops
- The drug is delivered to the brain by smell



Pharmaceutical safety and photo toxicity test

Photo toxicity test

- In vitro phototoxicity test:
  3T3 neutral red uptake phototoxicity test
- In vivo photo toxicity test:
  single dose/repeated dose photo toxicity test



Type of test

- Aggressive testing
- hemolysis test
- hypersensitive test
- Phototoxicity test of neutral red uptake in 3T3 cells in vitro
- In vivo photo toxicity test

Species

- Rat, rat
- rabbit
- non-human primate

route of medication

- Excitatory tests:
  intravenous injection, subcutaneous injection, intradermal injection, intramuscular injection, intraperitoneal injection, topical administration, vaginal administration, mucosal administration, inhalation administration, etc
- Hemolysis test:
  human blood, rabbit blood, monkey blood or in vivo hemolysis (intravenous injection)
- Allergy tests:
  intravenous injection, subcutaneous injection, intradermal injection, intramuscular injection, intraperitoneal injection, topical administration, inhalation administration, etc
- In vivo photo toxicity test:
  oral gavage, intravenous injection, subcutaneous injection, intradermal injection, intramuscular injection, intraperitoneal injection, topical administration;

Service advantages

1、It can carry out a variety of drug administration stimulation tests, allergy tests and hemolysis tests.
2、In vitro tests can be carried out on a variety of systems (such as human blood, rabbit blood and monkey blood), and in vivo hemolysis tests can be further confirmed if necessary.
3、The in vitro 3T3 cell neutral red uptake photo toxicity test has been successfully verified by PMDA of Japan.

Pathology

General anatomy
- whole organ dissection and sampling of rats, mice, dogs, monkeys, rabbits and pigs

Conventional H E section staining
- rat, mouse, dog, monkey, rabbit, pig whole organ H E section staining

Histopathology diagnosis
- Toxicology team led by DJSTP&JCVP experts

Non-clinical trial pathology consultation and histopathology peer review

Pathological section scanning (digital remote pathology diagnosis)

Database of experimental animal background of self-lesion

Immunohistochemical staining of various markers
- IgG, C3 immune complex
- CD3、CD20、CD68
- Cell keratin (CK)
- Wave protein (Vimentin)
- Keratin (Desmin)
- α-smooth muscle actin (α-SMA)
- Myoglobin (Myoglobin)
- CD34
- S-100
- Ion calcium binding linker molecule 1 (Iba 1)
- Gliadin fibrillar acid protein (G FAP)
- Ki-67, proliferating cell nuclear antigen (PCNA)
- Calcitonin (Calcitonin)
- glucagon
- insulin

Various special staining
- PAS staining (perinacet-aldehyde Schiff staining)
- Masson Three-color dyeing
- Toluidine blue staining
- Von Kossa Chroming
- prussian blue staining
- Modified Gomori Ammon-ia silver staining
- Victoria Blue dye
- PTAH staining (phosphotu-ngstic acid hematoxylin st-aining)
- Congo red staining
- Victoria Blue dye
- Ali Xins indigo dyeing
- Oil red staining
- LB staining (fast blue staining)

clinical pathology

- Conventional histopathological sections
- Aperio system for pathological section scanning (digital remote pathology diagnosis)
- Pathology peer review (Peer Review)
- Various immunohistochemical tissue markers
  -Lymphocyte classification marker staining
  -Tumor source identification staining
  -Circular immune complex staining
- A variety of special staining
  -Melanin staining classification (including hemosiderin, Prussian blue staining)
  -staining (glycogen staining)
  -Masson Trichromatic staining (collagen fiber staining)
  -Congo red staining (amyloid staining)
  -Tetraethylammonium blue staining (histiocyte staining)





Organize Cross TCR

- TCR试验类型
  -人源化单抗
  -多特异性抗体
  -抗体-药物偶联 (ADC、PDC)
  -纳米抗体
  -细胞因子融合蛋白
- TCR试验平台优势
  -遵循GLP法规的TCR平台
  -全种属试验动物和正常人体组织样本库
  -石蜡组织和冰冻组织TCR能力
  -配备生物安全等级二级实验室 (P2实验室)
  -TCR试验同行评议服务





Representative cases

Representative case study [Small molecule drug]

A small molecule drug

- The main metabolites of hepatic microsomes in different species



Human: M1 | Monkeys: M1 | Dogs: M4-2和M4-3 | Rats: M1和M4-3

Species selection

- The main metabolic pathway of the test substance in human, monkey and mouse liver microsomes is original oxidation and dehydrogenation, while the main metabolic pathway in dog and rat liver microsomes is single oxidation and oxidation dehydrogenation. According to the study of liver microsomal metabolism, it is believed that the metabolic characteristics of monkey, mouse and human are similar.
- M4-2 is a highly toxic metabolite. The high dose of crab-eating monkey is 25mg/kg (about 5 times the effective dose), and the animals tolerate the drug well after 28 days of administration

Representative case presentation [Specific antibodies]

A multi-specific antibody

- Efficacy in animal model: 0.01 mpk
- Preliminary experiment: IV, 1 time/day, 28 days

sex	fatalism	Dose group	C_{max} (ng/mL) Mean ± SD
Male	D1	L	842 ± 234
		M	3721 ± 432
		H	22558 ± 2760
	D14	L	410 ± NA
		M	1102 ± NA
		H	4230 ± 248
	D22	L	14 ± NA
		M	6 ± NA
		H	287 ± NA

- D14 There was a blood concentration at the Cmax point only after the end of drug administration
- ADA detection found that D10 began to produce ADA and had neutralizing activity
- Animal body weight and toxicity changes gradually recovered in the later stage

GLP trial

- **design**
  - Dosage: 1x,3x,10x
  - IV, 1 time/day, 28D+28D
  - Standard endpoints: weight, clinical observation, temperature, ECG, ophthalmology, clinical pathology, pathology
  - Special endpoints: cytokines, toxicity, ADA, neutralizing activity, absolute lymphocyte count, activated lymphocytes, RO, etc
  - Add midline anatomy
- **bear fruit**
  - The toxicity was greater in the middle period, and most of the patients had begun to recover by the end of the drug administration

focus

- Immunogenicity has an effect on TK
- Immunogenicity affects toxicity
- Pay attention to the results of the preliminary experiment, adjust the experimental design in time if necessary, and increase the mid-term dissection

www.innostar.cn

Representative case presentation [ADC drug]

Evaluation of ADC design of prodrug

- Characteristics of ADC structure in prodrug design



- Representative case presentation [ADC drug]

Activity and toxicity characteristics of each component

Drug>>>>Pro-drug ≈ Linker-pro-drug

Comparison of in vitro activity			
Test Article	Dose group	Dose Level	Main study (Mortality)
Drug	Low Dose	15	4/10
Drug	High Dose	45	10/10
Pro-drug	Low Dose	600	0/10
Pro-drug	High Dose	1800	10/10
Linker-pro-drug	Low Dose	600	2/10
Linker-pro-drug	High Dose	1800	10/10

The toxicity characteristics of ADC, pro-drug and linker-pro-drug were consistent with those of Drug

Correlation between toxicity and exposure of each component

Exposure comparison							
Test Article	Dose group	Dose Level	Main study (Mortality)	AUC		C_{max}	
				Drug	Pro-Drug	Drug	Pro-Drug
Drug	Low Dose	15	4/10	16	NA	43	NA
Drug	High Dose	45	10/10	120	NA	130	NA
Pro-drug	Low Dose	600	0/10	**2.5**	900	**1.9**	2100
Pro-drug	High Dose	1800	10/10	55	4900	38	9100
Linker-pro-drug	Low Dose	600	2/10	NA	NA	NA	NA
Linker-pro-drug	High Dose	1800	10/10	NA	NA	NA	NA

Drug or prodrug was not detected in the plasma of animals in the ADC group, and the plasma shedding rate of animals in vitro was <0.3%

Representative case

Representative case presentation [ADC drug]

GLP experiment design

- **Summary of preliminary experimental results**
  - The activity of Drug was much higher than that of other components, and the toxicity was related to the activity
  - The toxicity expression of ADC, Pro-drug and linker-pro-drug was consistent with that of Drug, suggesting that Drug was the main source of toxicity
  - The Pro-drug and Drug of ADC group were below the detection limit, indicating less shedding in peripheral circulation

Test article	Group
Vehicle	Control
ADC	Low dose
ADC	Mid dose
ADC	High dose
Drug	Equal molar of drug in ADC high dose

NMPA、FDA
Application approved

- **TK test substance**
  - ADC group: ADC, Tab, Drug, Pro-drug
  - Drug group: Drug



Representative case study [siRNA]

Drug: siRNA | Indications: Hypercholesterolemia | Stage: IND

test item	experiment design
Safety pharmacological tests	In vitro tests: None In vivo test: repeated drug administration toxicity test with monkeys (CV+RP+CN)
Pharmacokinetic studies	Absorption: single subcutaneous or intravenous pharmacokinetics study in monkeys; single subcutaneous or intravenous pharmacokinetics study in SD rats; Distribution: rodent (rat) tissue distribution test; mouse, rat, monkey or human plasma protein binding test; Metabolism and excretion: rat excretion and metabolism test; in vivo metabolite identification (rat + monkey plasma and liver homogenate); study on the metabolic stability of plasma and liver S9 in mice, rats, monkeys and human and identification of metabolites; Drug interactions: study of reversible and time-dependent inhibition of CYP enzymes and induction of CYP enzymes in human hepatocytes; transporter tests (ABC + SLC)
General toxicology tests	**SD rats:** repeated administration for 4 weeks followed by 8 weeks of toxicity test; NOAEL: high dose **Rhesus monkey:**repeated dosing for 4 weeks followed by 8 weeks of toxicity test; NOAEL: high dose
Reproductive and developmental toxicity tests	Not carried out
genetic toxicity test	Ames, in vitro chromosomal aberration test and mouse bone marrow micronucleus test--negative
carcinogenicity test	Not carried out
Drug formulation safety	Local irritation test (with long toxicity), hemolysis test, active allergy test



Project Experiences

920+ Clients Globally

100+ IND PKGs Annually

30+ NDA/BLA PKGs Annually

Rich experience in new drug research services that meet domestic and international application standards.

FDA	130+ INDs	3 NDA/BLAs
OECD BETTER POLICIES FOR BETTER LIVES	9 INDs	2 NDA/BLAs
NATIONAL MEDICAL PRODUCTS ADMINISTRATION 国家药品监督管理局		25 NDA/BLAs

独立行政法人 医薬品医療機器総合機構 Pharmaceuticals and Medical Devices Agency

Ministry of Food and Drug Safety

Australian Government Department of Health and Aged Care Therapeutic Goods Administration

Overview of Project Experiences

pharmaceutical chemicals	.....	Molecular glue drugs	PROTAC medicinal	Peptide drugs	Special preparations Liposomes, microspheres, microneedles, fluid crystals, micelles, etc	Small molecule chemical drugs All kinds of innovation targets
biologicals	Carrier delivery of drugs	recombination protein	fusion protein	Microecological products probiotics	Antibody drugs Monoclonal antibodies, bispecific antibodiesPolyantibody (triple antibody, quadruple antibody), TCENano-antibodies	Coupled drugs ADC (single target, double antibody, double payload), PDC, RDC, AOC
Cell / gene therapy medicinal	.....	Oncolytic drugs Oncolytic bacteria, oncolytic viruses	Gene therapy products Viral vectors, non-viral vectors gene editing..	Immune cell therapy products CAR-T, TIL, TCR-T, DC cells, Treg, CAR-M	Stem cell therapy products iPSC, MSC, HSC, etc	
Vaccines and drugs	.....	Therapeutic vaccines Therapeutic cancer vaccines (PCV-TAA, TSA)	prophylactic vaccine Inactivated/virus attenuated, recombinant protein vaccine, mRNA vaccine, etc			
Nucleic acid drugs	.....	miRNA	Aptamer	ASO	circRNA	siRNA
radiopharmaceuticals	.....	For diagnostic use only radiopharmaceutical	For therapeutic use radiopharmaceuticals			
traditional Chinese medicine	.....	Ancient classic prescription Chinese medicine compound preparation	compound preparation	traditional Chinese medicine Improved new drugs	Chinese medicine innovation drugs	

Enabling 200+ World-first and Domestic-first Innovative Drug Development Services

Overseas

Cell & Gene Therapy Products

- First TIL Cell Therapy Product that Does Not Require Elution and IL-2 Injection with IND Approved
- First Genetically Engineered Oncolytic Bacteria Product with IND Approved
- First Oncolytic Virus Product with INDs Approved by NMPA, FDA and TGA
- First Oncolytic Bacteria Product with IND Approved

Anti-body Drugs

- First Anti-PD1/CTLA4 Bispecific Antibody with BLA Approved by NMPA and IND Approved by FDA
- First Tetra-specific Antibody with IND Approved
- First Anti-BTLA Monoclonal Antibody with IND Approved
- First Small Molecular Oral PCSK9 Inhibitor with IND Approved
- First Anti-fibrosis Drug Discovered by AI with IND Approved

ADC Drugs

- First ADC Targeting GPRC5D with IND Approved

Other New Modalit

China

Cell & Gene Therapy Products

- First Non-viral Vector CAR-T Cell Therapy Product with IND Approved
- First Human Amniotic Epithelial Derived Stem Cell Product with IND Approved
- First Cardiomyocyte Therapy Product Derived from Human Induced Pluripotent Stem Cells (hiPSC) with IND Approved
- First Exosome Aerosol Product Derived from Human Adipose Mesenchymal Cells with IND Approved

Anti-body Drugs

First Anti-PD1 Monoclonal Antibody (LOQTORZI™), BLAs Approved by NMPA and FDA

君实生物 TopAlliance

- First Nanosized Anti-PD1 Antibody Using Erythrocytes as Carrier with IND Approved
- First MET Inhibitor with NDA Approved by NMPA
- First BCL-2 Inhibitor with IND Approved

Other New Modalit

ADC Drugs

- First Anti-EGFR/HER3 Bispecific ADC with IND Approved

Radiopharmaceutica

- First In-vivo Radioactive Diagnostic Drug for Alzheimer's Disease with IND Approved

Fusion Protein

- First BCL-2 Inhibitor with IND Approved
  First Long-acting FGF21 Fusion Protein with IND Approved

Service Quality Recognition

InnoStar serviced License out projects **40+**

TOP MNC Celebrity Licensee

Pfizer
Takeda
...
Novartis
Merck
Bristol Myers Squibb
AstraZeneca

Licensor	Licensee	Project	Product Category
百利天恒 BIOKIN PHARMACEUTICAL	Bristol Myers Squibb	BL-B01D1	ADC
恒瑞	HLB-LS	Pyrotinib	EGFR/HER2/HER4 Tyrosine Kinase Inhibitors
恒瑞	Dong-A Pharma	SHR-1701	Anti-PD1/TGF-RII Fusion Protein
恒瑞	Biotherapeutics/Reistone Biopharma	SHR0302	JAK1 Inhibitor
LaNova 礼新医药	AstraZeneca	LM-305	ADC
LaNova 礼新医药	Turning Point /Therapeutics Bristol Mlyers Squibb	LM-302	ADC
EXCURE BIOPHARMA	Syncromune	YH-002	Anti-OX40 Antibody
科望制药 A gu Biopharma	Novartis	BW-05	siRNA
恒瑞	IDEAYA Biosciences	SHR-4849	ADC
恒瑞	Hercules	HRS-7535 HRS-9531 HRS-4729	Small molecule GLP-1 agonists Peptide GLP-1/G IP Next-generation enteral insulin products
LaNova 礼新医药	Merck	LM-299	VEGF+PD-1

INNOSTAR

益诺思 INNOSTAR

Shanghai InnoStar Biotechnology Co., Ltd

SHANGHAI HEADQUARTERS
No. 199 Guoshoujing Road, China (Shanghai) Pilot Free Trade Zone
BUSINESS CONSULTING
Tel:+86-21-60211999
Email: services@innostar.cn marketing@innostar.cn

Scan the code to follow